sacituzumab govitecan,Pembrolizumab,Avelumab,Zimberelimab,Domvanalimab
Gilead Sciences,Merck,Pfizer,Arcus Biosciences,Otsuka
['muc ,(-much)', 'sacituzumab', ' sg ', 'tropics-04', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'bladder']
to close out rapid abstracts #gu23, #trophyu01 cohort 2 by : phase 2 of sacituzumab in platinum-ineligible metastatic bladder cancer (muc) after io orr 32% after io, 53% for chemo/ev-naive ae: cytopenias (many need gcsf), fatigue, diarrhea 
GU Oncologist | 🇨🇦 GU & NOLA Heme/Onc Alumni | Interested in GU, Immuno Onc & Med Ed | @ASCO Featured Voice | @TwoOncDocs podcast